Agenus Inc. , a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

$AGEN "Curing cancers with innovation and speed". https://t.co/NGvTlOeqIt
@Agenus_Bio is designed to reach tailored cancer cure quickly at affordable prices: Without any doubt, that's the key to maintain the perfect balance between #innovation & rules governing the health sector.

$AGEN highlighted in Nature Biopharma Dealmakers edition. Curing cancers with innovation & speed - developing next-generation immunotherapeutics
designed to expand benefit for patients with cancer. https://t.co/V5SCJvnXaE

Announcement: $AGEN to Manufacture Clinical Supply of GS-1423 for Gilead #Immunotherapy #manufacturing https://t.co/Opxd1JB3he

KEY STEPS FORWARD! Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update https://t.co/KgHs3iYZq8 @Agenus_Bio @jbuell01 #biotech #cancer #oncology #digitalhealth

$AGEN advances another discovery, now clear to clinic; CD137 agonist, AGEN2373, which has been specifically designed to overcome
the shortcomings of earlier generation CD137 agonists. https://t.co/iKaOovP32I
#CD137 #Immunotherapy #Cancer

Agenus Reports Second Quarter 2019 Financial Results & Corporate Update https://t.co/8A37WBhcqo
- CTLA-4 & PD-1 trials on track; data expected 2H2019; Next gen CTLA-4 advances; $15M in cash milestones triggered cmpds advance; GSK's Shingrix sales projected $1.3Bn 2019

LATEST NEWSLETTER highlights Don Vidic, our Head of Commercial & expert in distribution strategy. With BLA filings on track for 2020, Don will defy encumbered norms to drive access to patients the $AGEN way - with innovation, focus, & speed. Read more https://t.co/187LgMpFL8

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Agenus Inc.

3 Forbes Road
Lexington, MA 02421

+1 (781) 674-4400

www.agenusbio.com

September 2019
S M T W T F S
« Aug    
1234567
891011121314
15161718192021
22232425262728
2930  

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account